Mission
At Ropana Vascular, we develop endovascular devices to fill significant unmet clinical needs in the treatment of cardiovascular disease.
Vision - Reduce Amputations
Peripheral Arterial Disease (PAD)
PAD affects > 200 Million patients worldwide and over 12 million in the United States.
Solving a Major Unmet Medical Need
Peripheral CTOs (Chronic Total Occlusions) are common in advanced PAD, with high failure rates in crossing.
CLTI (Chronic Limb Threatening Ischemia) is the most advanced and serious form of PAD.
Clinicians need a safer, more effective, less traumatic, and time saving crossing option.
Ropana Vascular's FirstPass IVL Catheter is being designed with the CTO in mind!
FirstPass*
IVL technology created as a time saving choice for crossing CTOs more efficiently and less traumatically.
*Currently under development - not FDA cleared
Under Development
Based on functional testing and visual inspection, our end-emitting lithotripsy catheter successfully crossed both gypsum and human calcified plaque.
Next Phase
Path Forward
Currently refining prototype with human artery testing (on amputated legs) and ongoing development of console/generator.
Additional sizes for above and below the knee applications.
Strategic work on patents - provisional and applied
Path Forward
Path Forward
Commercialize to profitability, disruption, and exit options.
FDA clearance - Go to market
- Commercialization leadership team is already in place.
- Revenue ramp focus on capturing growing peripheral CTO/IVL market, specifically in OBLs and ASCs.
Clinical Advisors and Key Opinion Leaders
Peter Soukas, MD
Kenneth Rosenfield, MD
Craig A. Thompson, MD
Director of Vascular Medicine and the Interventional Vascular Laboratories at The Miriam and Rhode Island Hospitals
Dr. Soukas is also the director of the Vascular & Endovascular Medicine Fellowship Program Dr. Soukas is a recognized expert on the interventional treatment of critical limb ischemia and endovascular treatment of both arteri
Director of Vascular Medicine and the Interventional Vascular Laboratories at The Miriam and Rhode Island Hospitals
Dr. Soukas is also the director of the Vascular & Endovascular Medicine Fellowship Program Dr. Soukas is a recognized expert on the interventional treatment of critical limb ischemia and endovascular treatment of both arterial and venous disease. He has delivered hundreds of invited lectures nationally and internationally and is a reviewer for several cardiovascular journals.
Craig A. Thompson, MD
Kenneth Rosenfield, MD
Craig A. Thompson, MD
Director, Cardiac Catheterization and Interventional Cardiology, Hartford Healthcare Network
Dr. Craig Alan Thompson is known for specializing in complex coronary interventions (including chronic total occlusions), structural heart procedures such as TAVR, peripheral arterial disease, and catheter-based therapies.
Prior leadership roles in
Director, Cardiac Catheterization and Interventional Cardiology, Hartford Healthcare Network
Dr. Craig Alan Thompson is known for specializing in complex coronary interventions (including chronic total occlusions), structural heart procedures such as TAVR, peripheral arterial disease, and catheter-based therapies.
Prior leadership roles include, Senior Vice President and Chief Medical Officer for Interventional Cardiology at Boston Scientific (2014–2021)
Kenneth Rosenfield, MD
Kenneth Rosenfield, MD
Kenneth Rosenfield, MD
Kenneth Rosenfield, MD, MHCDS, MSCAI, is a leading interventional cardiologist and Section Head for Vascular Medicine and Intervention at Massachusetts General Hospital (with a faculty appointment at Harvard Medical School), specializing in complex cardiac and vascular procedures including carotid, renal, and peripheral artery disease, critical limb ischemia, and pulmonary embolism.
Venkatesh Ramaiah, MD
Kenneth Rosenfield, MD
Kenneth Rosenfield, MD
Dr. Ramaiah is the co-founder of Pulse Cardiovascular Institute in Scottsdale, Arizona.
Dr. Ramaiah is a vascular and endovascular surgeon specializing in complex aortic aneurysms, peripheral arterial disease, carotid disease, and venous disorders, with more than 25 years of experience. He has authored over 90 peer-reviewed publications an
Dr. Ramaiah is the co-founder of Pulse Cardiovascular Institute in Scottsdale, Arizona.
Dr. Ramaiah is a vascular and endovascular surgeon specializing in complex aortic aneurysms, peripheral arterial disease, carotid disease, and venous disorders, with more than 25 years of experience. He has authored over 90 peer-reviewed publications and textbook chapters, has served as principal investigator on multiple endovascular device trials, and has been recognized among America’s leading vascular surgeons.
Fadi A. Saab, MD
Vijay Ramanath, MD CMO
Fadi A. Saab, MD
Medical Director of Endovascular Therapy and Director of Cardiovascular Research at centers including Michigan Outpatient Vascular Institute and Advanced Cardiac & Vascular Centers for Amputation Prevention.
Dr. Saab, MD, FACC, FSCAI, FASE, is an interventional cardiologist specializing in endovascular revascularization for peripheral vasc
Medical Director of Endovascular Therapy and Director of Cardiovascular Research at centers including Michigan Outpatient Vascular Institute and Advanced Cardiac & Vascular Centers for Amputation Prevention.
Dr. Saab, MD, FACC, FSCAI, FASE, is an interventional cardiologist specializing in endovascular revascularization for peripheral vascular disease and critical limb ischemia (CLI), as well as venous disease and general cardiac care
Karan Bhalla, MD
Vijay Ramanath, MD CMO
Fadi A. Saab, MD
Karan S. Bhalla, MD, FACC, FSCAI, RPVI, is a board-certified interventional cardiologist specializing in cardiovascular diseases, coronary interventions, peripheral vascular disease, and related therapies, practicing in the southeast Houston area (Pasadena, Friendswood, and Houston).
Vijay Ramanath, MD CMO
Vijay Ramanath, MD CMO
Vijay Ramanath, MD CMO
Vijay S. Ramanath, MD, FACC, FSCAI, is a board-certified interventional cardiologist specializing in complex coronary procedures, peripheral vascular interventions (including techniques to prevent leg amputations), catheter-based therapies for blood clots, TAVR, and minimally invasive treatments for varicose veins.
Dr. Ramanath practices in the Plano/Frisco area of Texas.
Business and Strategy Advisors
Terry Coutsolioutsos
Terry Coutsolioutsos
Terry Coutsolioutsos
Terry is a veteran Med Device Executive who also rolls up his sleeves to get the work done.
SVP at Siemens Healthineers managing a $5B North American portfolio across multiple sales divisions and 1,500 sales professionals.
Division Vice President at Abbott Vascular managing $650M in IDN relationships and $1B+ in GPO contracts.
Over a decad
Terry is a veteran Med Device Executive who also rolls up his sleeves to get the work done.
SVP at Siemens Healthineers managing a $5B North American portfolio across multiple sales divisions and 1,500 sales professionals.
Division Vice President at Abbott Vascular managing $650M in IDN relationships and $1B+ in GPO contracts.
Over a decade at Boston Scientific building consultative sales organizations from the ground up.
https://www.linkedin.com/in/terry-coutsolioutsos/
Bryan Osterhaus
Terry Coutsolioutsos
Terry Coutsolioutsos
Bryan has built several businesses from the ground up, starting in the early 1990's and continuing to the present.
His entrepreneurial drive has led him to start medical device and distribution companies in the orthopedic space as well as outside of orthopedics.
Bryan's leadership style and commercial vision are strong additions to the team and we look forward to his wisdom and advice.
Leadership Team
Vijay - Founder and CMO
Vijay - Founder and CMO
Vijay Ramanath, MD, FACC, FSCAI
Ropana Vascular Founder
Interventional Cardiologist with 15+ years of clinical expertise, with an entrepreneurial mindset and multiple patents.
James - CEO
Vijay - Founder and CMO
James Lowry
Ropana Vascular CEO
35 years of leadership in medical device sales, marketing and consulting to startups, scaleups and global corporations.
Jim - CTO
Jim Harrison, BS MS,
Ropana Vascular CTO
A proven track record of delivering innovative medical devices that transform patient care. He has led teams to 18 clinical trials, 10 IDE approvals, and 3 PMA Class III approvals while driving two acquisitions exceeding $500M and mentoring high-performing R&D teams.
Robert - COO
Robert Dorsher, MBA
Ropana Vascular COO
40 years of medical device leadership in strategic commercialization, operations and planning.